Targeting Telomeres to Clear Cancer - Vlad Vitoc at Longevity Summit Dublin 2023

แชร์
ฝัง
  • เผยแพร่เมื่อ 10 พ.ย. 2024

ความคิดเห็น • 8

  • @SirTenenbaum
    @SirTenenbaum ปีที่แล้ว +5

    MAIA Biotechnology deserves SO much more attention than it's gotten. I'm super glad Regeneron has noticed and begun collaboration in clinical trials.

  • @williamwalker6071
    @williamwalker6071 ปีที่แล้ว +2

    About time... the preclinicals were done in 2015.

  • @royceross5896
    @royceross5896 7 หลายเดือนก่อน +1

    MAIA has arrived and is here to stay! I think we will be hearing a lot more from them in the future...

  • @andrewwalker8985
    @andrewwalker8985 ปีที่แล้ว +1

    They’ve basically cured cancer??

  • @bionanoscience
    @bionanoscience 7 หลายเดือนก่อน

    It would have been helpful to the audience in this presentation to have made a more explicit distinction between the human data and the preclinical data in mice. All of the comments about "extraordinary" or "curative" were in relation to data collected in mouse experiments, not trials in humans. Hopefully, the drug is as effective in humans, although the data released thus far appears to not support this. This is not to say the drug won't be a much needed improvement over the current standard of care, but frankly, not making this explicit distinction in the data presentation was a little misleading.

    • @badfish8453
      @badfish8453 7 หลายเดือนก่อน

      Human trials are underway. So results are TBD. Starts with mice then into human trials. So far, all good readouts in patients

    • @zhushishuo
      @zhushishuo 5 หลายเดือนก่อน

      So far the data on human far exceeds standard of care, chemo